Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Bringing about digital health change

Qualcomm's Rick Valencia on what the future could hold

- PMLiVE

Janssen’s myeloma drug wins FDA priority review

Monotherapy daratumumab to be reviewed within six months

- PMLiVE

mRNA – message received

Assessing the growing pharma interest in modified messenger RNA

- PMLiVE

EM Imaging appoints new chairman

John Jeans to bring firm to forefront of molecular imaging market

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

UK Life Sciences Strategy - one year on

Genome diagnostic can see if a patient is ‘ageing well’

Test can predict risk of age-related diseases and age of death

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

- PMLiVE

First-ever World Hepatitis Summit calls for national programmes

Follows rise in hepatitis deaths for fifth consecutive year

- PMLiVE

NICE turns down Celgene’s Otezla once again

Concludes the drug's cost outweighs its benefit for psoriatic arthritis

Novartis day

Novartis’ Farydak gets nod for myeloma in Europe

HDAC inhibitor offers new mechanism of action in fight against myeloma

- PMLiVE

Novartis launches first biosimilar Zarxio in the US

Follows Amgen's failure to block Neupogen-version from release

- PMLiVE

Pharma perspectives: communications creativity (part 2)

David Higgins from Sudler & Hennessey Group on what it means to be creative in healthcare communications

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links